Q-omics provides the consensus-scored CCNQP3 profile across patient tissues and cancer cell-line models. CCNQP3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CCNQP3 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, CCNQP3 RNA expression shows 5,141 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight LIHC, COAD, and UCEC as cancer lineages where CCNQP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNQP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNQP3 survival associations across molecular data types. CCNQP3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNQP3 RNA expression–survival associations across cancer types. High CCNQP3 expression shows unfavorable associations in LIHC, BRCA, STAD, HNSC and MESO, but favorable associations in CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CCNQP3 RNA expression.
This table summarizes CCNQP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CCNQP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNQP3 shows lower tumor expression in STAD and higher tumor expression in COAD, LUAD and LIHC. The COAD box plot shows higher CCNQP3 RNA expression in tumor versus normal tissue (log2 FC = +0.155, t-test p < 0.001).
This table shows molecular features associated with CCNQP3 in patient tissues and cancer cell lines. In patient samples, CCNQP3 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
